DraftKings, the online sports betting company, saw an increase in its stock price on Friday following the release of its solid third-quarter financial results. Analysts on Wall Street expressed their optimism about the company's performance.

Benchmark analyst Mike Hickey maintained his Buy rating on the stock, setting a price target of $37. He noted that DraftKings has effectively acquired new customers and maintained high levels of customer engagement.

During the quarter, DraftKings reported an increase in monthly unique players to 2.3 million, marking a 40% jump from the previous year. The average revenue per monthly unique player also saw a 14% increase, amounting to $114.

In terms of financials, DraftKings posted a third-quarter loss of 61 cents per share on revenue of $790 million. This surpassed analysts' expectations, as they predicted a loss of 69 cents per share on revenue of $704.9 million. In the same period last year, the company had reported a loss of $1 per share on revenue of $501.9 million.

Truist Securities analyst Barry Jonas, who rates the stock as a Buy with a $44 price target, emphasized DraftKings as one of the best growth stories in the gaming industry. He expressed strong conviction that DraftKings will be a long-term winner in the interactive space.

Despite a more saturated competitive environment, DraftKings raised its 2023 revenue guidance to be between $3.67 billion and $3.72 billion. This is an increase from its previous forecast of $3.46 billion to $3.54 billion.

Chief Executive Jason Robins credited the company's product and technology investments, as well as excellent preparation and execution by the entire organization, for their fantastic third-quarter results.

Overall, DraftKings continues to demonstrate its strength and potential in the online sports betting market.

Apple's China Problem Persists

Bank of America Shares Surge Amid Positive Jobs Data

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Challenges for Hikma Pharmaceuticals in North America
News

Challenges for Hikma Pharmaceuticals in North America

Hikma Pharmaceuticals faces challenges in its injectables business in North America due to supply and capacity constrain...

The Promise and Shortcomings of Artificial Intelligence in the Federal Courts
News

The Promise and Shortcomings of Artificial Intelligence in the Federal Courts

Chief Justice John Roberts explores the potential and drawbacks of artificial intelligence in the federal courts, emphas...

Datadog Stock Surges on Strong Quarterly Results and Optimistic Outlook
News

Datadog Stock Surges on Strong Quarterly Results and Optimistic Outlook

Datadog experiences a surge in stock value after exceeding profit expectations in Q3 and providing a positive outlook fo...

Auto1 Group Adjusts Sales Outlook and Aims for Narrowed Loss
News

Auto1 Group Adjusts Sales Outlook and Aims for Narrowed Loss

Auto1 Group revises sales projection, expects sales of 625,000 units, and aims to achieve a narrower adjusted loss. Reve...